Clinical Trial Update: A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

View source ↗

Summary

Vismodegib (GDC-0449) received marketing approval for use in locally advanced or metastatic basal cell carcinoma, per the clinical trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Basal Cell Carcinoma | Status: APPROVED_FOR_MARKETING